Role of hepatoprotective drugs in the treatment of fatty liver disease
-
-
[1]Eriksson S, Eriksson KF, Bondesson L.Nonalcoholic steatohepati-tis in obesity:a reversible condition[J].Acta Med Scand, 1986, 220 (1) ∶83-88. [2]Day CP.Natural history of NAFLD:remarkably benign in the ab-sence of cirrhosis[J].Gastroenterology, 2005, 129 (1) ∶375-378. [3]Ueno T, Sugawara H, Sujaku K, et al.Therapeutic effects of re-stricted diet and exercise in obese patients with fatty liver[J].Hep-atol, 1997, 27 (1) ∶103-107. [4]Suzuki A, Lindor K, Saver JS, et al.Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease[J].Hepatol, 2005, 43 (6) ∶926-928. [5]Comar KM, Sterling RK.Review article:Drug therapy for non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther, 2006, 23 (2) ∶207-215. [6]Chen SM, Liu CY, Li SR, et al.Effects of Therapeutic Lifestyle Program on Ultrasound-diagnosed Nonalcoholic Fatty Liver Disease[J].Journal of the Chinese Medical Association, 2008, 71 (11) ∶551-558. [7]范建高, 曾民德.保肝药物在脂肪性肝病防治中的应用.脂肪性肝病[M].北京:人民卫生出版社, 2005∶475-484. [8]Torres DM, Harrison SA.Diagnosis and Therapy of Nonalcoholic Steatohepatitis[J].Gastroenterology, 2008, 134 (6) ∶1682-1698. [9]Dufour JF, Oneta CM, Gonvers JJ, et al.Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonal-coholic Steatohepatitis[J].Clin Gastroenterol Hepatol, 2006, 4 (12) ∶1537-1543. [10]邓银泉, 范小芬.水飞蓟素治疗非酒精性脂肪性肝炎的临床观察[J].中国中药杂志, 2005, 30 (3) ∶1044. [11]Sanyal AJ, Mofrad PS, Contos MJ, et al.Apilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis[J].Clin Gastroenterol Hepatol, 2004, 2 (12) ∶1107-1115. [12]Lieber CS.Pathogenesis and treatment of alcoholic liver disease:progress over the last50years[J].Rocz Akad Med Bialymst, 2005, 50∶7-20.
本文二维码
计量
- 文章访问数: 2220
- HTML全文浏览量: 2
- PDF下载量: 738
- 被引次数: 0